New combo therapy aims to shrink prostate cancer DNA in blood
NCT ID NCT04109729
First seen Nov 21, 2025 · Last updated Apr 30, 2026 · Updated 13 times
Summary
This early-phase study tests a combination of two drugs—nivolumab (an immunotherapy) and Radium-223 (a radioactive drug)—in 39 men with advanced prostate cancer that has spread to bones and no longer responds to hormone therapy. The main goals are to check safety and see if the treatment reduces tumor DNA in the blood after 6 weeks. Participants must have symptomatic bone metastases and adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.